StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) shareholders

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)

Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
86.0%
56M of 65M shares
Institutional holders
201
36 new, 38 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
1 buys · 23 sales
Net sold $1.15M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.5,422,7967.90%13G (passive) amendmentMar 31, 2025
Logos Global Management LP
Joint filing with Logos Global Management GP LLC (6.40%), Arsani William (6.40%)
4,800,0006.40%13D (active)Jun 9, 2025
Vanguard Portfolio Management3,917,6716.12%13G (passive)Mar 31, 2026
D. E. Shaw & Co., L.P.
Joint filing with David E. Shaw (5.40%)
3,495,1535.40%13G (passive) amendmentJun 30, 2026
David E. Shaw
Joint filing with D. E. Shaw & Co., L.P. (5.30%), D. E. Shaw & Co., L.L.C. (5.20%)
3,405,0265.30%13G (passive)Nov 6, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ARVNValueChange% of portfolio
BlackRock, Inc.7,609,12311.64%$63.23M+811,5390.00%
Vanguard Portfolio Management LLC4,123,3996.31%$34.27M+233,7710.00%
D. E. Shaw & Co., Inc.3,495,1535.35%$29.04M−143,4140.01%
Pfizer Inc3,457,8155.29%$27.66M–16.24%
Armistice Capital, LLC2,796,0004.28%$23.23M+818,0000.28%
Vanguard Capital Management LLC2,714,1634.15%$22.55M+24,8010.00%
Two Sigma Investments, LP2,573,4473.94%$21.39M+741,3330.02%
State Street Corp2,196,8723.36%$18.26M+368,4000.00%
Geode Capital Management, LLC1,667,2652.55%$13.86M+110,1580.00%
Qube Research & Technologies Ltd1,592,2762.44%$13.23M+390,6410.01%
Jacobs Levy Equity Management, Inc1,412,6432.16%$11.74M−28,8780.04%
Federated Hermes, Inc.1,356,0322.07%$11.27M+215,3170.02%
Nextech Invest, Ltd.1,122,7131.72%$17.12M+583,3190.81%
Acadian Asset Management LLC848,3821.30%$7.05M−101,4920.01%
Hillsdale Investment Management Inc.750,9001.15%$6.24MNew0.14%
Price T Rowe Associates Inc /Md/728,1471.11%$6.05M+301,0540.00%
TCG Crossover Management, LLC707,0981.08%$5.88M−1,680,3630.14%
Dimensional Fund Advisors LP654,9091.00%$5.44M+169,1450.00%
Goldman Sachs Group Inc640,8110.98%$5.33M−116,0640.00%
Citadel Advisors LLC620,9730.95%$5.16M−560,0150.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202620156M86.0%36 / 8053 / 3810M8M
Q1 202620754M82.9%34 / 6371 / 3214M9M
Q4 202520656M85.7%32 / 6972 / 3111M20M
Q3 202521167M100.0%35 / 6872 / 3913M16M
Q2 202521570M100.0%53 / 7554 / 5223M18M
Q1 202521565M99.6%56 / 7160 / 3618M27M
Q4 202419877M100.0%29 / 7953 / 3515M13M
Q3 202420675M100.0%27 / 7265 / 2714M6M
Q2 202420773M100.0%28 / 9055 / 407M5M
Q1 202422372M100.0%38 / 8566 / 2510M6M
Q4 202321268M100.0%83 / 6743 / 2325M6M
Q3 202315449M74.7%20 / 6250 / 205M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

198 funds held ARVN in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ARVNValue% of fundAs of
Vanguard Total Stock Market Index Fund1,920,6822.94%$15.96M0.00%Jun 30, 2026
Vanguard Strategic Equity Fund1,709,9172.62%$14.21M0.12%Jun 30, 2026
iShares Russell 2000 ETF1,550,3642.37%$12.88M0.02%Jun 30, 2026
Vanguard Explorer Fund896,3721.37%$7.20M0.03%Jul 31, 2026
Vanguard Extended Market Index Fund727,4281.11%$6.04M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund648,8420.99%$5.21M0.02%Jul 31, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF642,9280.98%$5.34M1.25%Jun 30, 2026
Federated Hermes MDT Small Cap Core Fund561,3010.86%$4.51M0.20%Jul 31, 2026
BlackRock Advantage Small Cap Core Fund529,7280.81%$4.76M0.09%May 29, 2026
iShares Russell 2000 Value ETF507,1090.78%$4.21M0.03%Jun 30, 2026
Vanguard Strategic Small-Cap Equity Fund488,6930.75%$4.06M0.13%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.407,6480.62%$3.39M0.02%Jun 30, 2026
iShares Biotechnology ETF383,6150.59%$3.19M0.04%Jun 30, 2026
Fidelity Extended Market Index Fund335,3050.51%$3.01M0.01%May 31, 2026
Fidelity Enhanced Small Cap Core ETF322,5260.49%$2.68M0.05%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Randy TeelPresident and CEO, Director285,0090.44%May 22, 2026
David K. LoomisVP, Chief Accounting Officer39,9610.06%Nov 9, 2026
Andrew SaikChief Financial Officer187,4320.29%Jun 24, 2026
Angela M. CacaceChief Scientific Officer180,3900.28%Jun 18, 2026
Noah BerkowitzChief Medical Officer191,3950.29%May 13, 2026
Ian TaylorPresident, R&D160,7850.25%Feb 25, 2025
Everett CunninghamDirector41,5720.06%Jun 26, 2026
Briggs MorrisonDirector111,5480.17%Jun 26, 2026
Linda BainDirector41,5720.06%Jun 26, 2026
Edward Moore Kennedy Jr.Director84,2900.13%Jun 26, 2026
Leslie V. NorwalkDirector41,5720.06%Jun 26, 2026
Alsup Laurie SmaldoneDirector41,5720.06%Jun 26, 2026
John G. HoustonDirector1,122,1831.72%Mar 2, 2026
Sunil AgarwalDirector30,1660.05%Jun 30, 2025
John D. YoungDirector26,0450.04%Jun 27, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
David K. Loomis
VP, Chief Accounting Officer
Nov 9, 2026Sale(10b5-1 plan)−232$6.36$1.48K39,961
Briggs Morrison
Director
Jun 24, 2026Award+15,527––111,548
Leslie V. Norwalk
Director
Jun 24, 2026Award+15,527––41,572
Linda Bain
Director
Jun 24, 2026Award+15,527––41,572
Everett Cunningham
Director
Jun 24, 2026Award+15,527––41,572
Edward Moore Kennedy Jr.
Director
Jun 24, 2026Award+15,527––54,957
Alsup Laurie Smaldone
Director
Jun 24, 2026Award+15,527––41,572
Andrew Saik
Chief Financial Officer
Jun 24, 2026Sale(10b5-1 plan)−5,696$8.16$46.48K187,432
Angela M. Cacace
Chief Scientific Officer
Jun 17, 2026Sale(10b5-1 plan)−2,576$7.60$19.58K180,390
Randy Teel
President and CEO, Director
May 21, 2026Sale−2,209$9.04$19.97K285,009
David K. Loomis
VP, Chief Accounting Officer
May 11, 2026Sale−1,919$9.94$19.07K40,193
Randy Teel
President and CEO, Director
May 11, 2026Sale−9,657$9.94$95.99K287,218
Andrew Saik
Chief Financial Officer
May 11, 2026Sale−11,139$9.94$110.72K193,128
Angela M. Cacace
Chief Scientific Officer
May 11, 2026Sale−9,657$9.94$95.99K182,966
Noah Berkowitz
Chief Medical Officer
May 11, 2026Sale−11,108$9.94$110.41K191,395
Noah Berkowitz
Chief Medical Officer
Mar 18, 2026Sale−6,435$11.10$71.43K202,503
Briggs Morrison
Director
Mar 6, 2026Buy+20,000$13.40$268.00K96,021
John G. Houston
Director
Feb 27, 2026Sale−11,787$13.14$154.88K1,122,183
John G. Houston
Director
Feb 27, 2026Sale−18,822$13.24$249.20K1,133,970
John G. Houston
Director
Feb 27, 2026Sale−4,688$13.24$62.07K1,152,792
Randy Teel
President and CEO, Director
Feb 26, 2026Award+147,179––296,875
Andrew Saik
Chief Financial Officer
Feb 26, 2026Award+45,000––204,267
Angela M. Cacace
Chief Scientific Officer
Feb 26, 2026Award+45,000––192,623
David K. Loomis
VP, Chief Accounting Officer
Feb 26, 2026Award+12,420––42,112
Noah Berkowitz
Chief Medical Officer
Feb 26, 2026Award+45,000––208,938
Randy Teel
President and CEO, Director
Feb 26, 2026Award+147,791––297,487
Randy Teel
President and CEO, Director
Feb 23, 2026Sale−3,748$12.16$45.58K149,696
Randy Teel
President and CEO, Director
Feb 23, 2026Sale−1,038$12.16$12.62K153,444
David K. Loomis
Chief Accounting Officer
Feb 23, 2026Sale−1,108$12.16$13.47K29,692
Angela M. Cacace
Chief Scientific Officer
Feb 23, 2026Sale−1,038$12.16$12.62K150,194
Angela M. Cacace
Chief Scientific Officer
Feb 23, 2026Sale−2,571$12.16$31.26K147,623
David K. Loomis
Chief Accounting Officer
Feb 13, 2026Sale−1,016$11.89$12.08K30,800
Randy Teel
President and CEO, Director
Feb 13, 2026Sale−4,403$11.89$52.35K154,482
Noah Berkowitz
Chief Medical Officer
Feb 13, 2026Sale−5,685$11.89$67.59K163,938
Andrew Saik
Chief Financial Officer
Feb 13, 2026Sale−5,134$11.89$61.04K159,267
Angela M. Cacace
Chief Scientific Officer
Feb 13, 2026Sale−4,592$11.89$54.60K151,232
David K. Loomis
Chief Accounting Officer
Nov 7, 2025Sale−230$9.89$2.27K31,697
Briggs Morrison
Director
Sep 22, 2025Buy+30,000$7.57$227.10K76,021
Sunil Agarwal
Director
Jun 25, 2025Award+16,025––30,166
Alsup Laurie Smaldone
Director
Jun 25, 2025Award+16,025––26,045
Linda Bain
Director
Jun 25, 2025Award+16,025––26,045
Edward Moore Kennedy Jr.
Director
Jun 25, 2025Award+16,025––39,430
Leslie V. Norwalk
Director
Jun 25, 2025Award+16,025––26,045
John D. Young
Director
Jun 25, 2025Award+16,025––26,045
Briggs Morrison
Director
Jun 25, 2025Award+16,025––46,021
Everett Cunningham
Director
Jun 25, 2025Award+16,025––26,045
Andrew Saik
Chief Financial Officer
Jun 24, 2025Sale−5,700$7.61$43.38K164,401
Angela M. Cacace
Chief Scientific Officer
Jun 17, 2025Sale−2,583$7.49$19.35K154,248
Noah Berkowitz
Chief Medical Officer
May 9, 2025Award+59,600––169,623
Angela M. Cacace
Chief Scientific Officer
May 9, 2025Award+59,600––156,831
David K. Loomis
Chief Accounting Officer
May 9, 2025Award+11,825––30,688
Andrew Saik
Chief Financial Officer
May 9, 2025Award+59,600––170,101
Noah Berkowitz
Chief Medical Officer
Mar 18, 2025Sale−8,658$8.59$74.37K110,023
Angela M. Cacace
Chief Scientific Officer
Feb 24, 2025Sale−3,061$16.75$51.27K98,377
Angela M. Cacace
Chief Scientific Officer
Feb 24, 2025Sale−1,146$16.55$18.97K97,231
John G. Houston
President and CEO, Director
Feb 24, 2025Sale−5,154$16.55$85.30K1,157,480
John G. Houston
President and CEO, Director
Feb 24, 2025Sale−26,184$16.75$438.58K1,162,634
David K. Loomis
Chief Accounting Officer
Feb 24, 2025Sale−1,214$16.75$20.33K18,863
Ian Taylor
President, R&D
Feb 24, 2025Sale−7,356$16.75$123.21K160,785
Ian Taylor
President, R&D
Feb 24, 2025Sale−1,664$16.55$27.54K159,121

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
9.54%
6M shares short
Days to cover
7.6
At 1M shares a day
Change since last report
+2.8%
From 6M shares
Short volume, 20 days
50.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arvinas's stock actually held short. Settlement fails (shares not delivered on time) peaked at 688 shares on Sep 8, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Sunil Agarwal
Director
Sep 22, 202623,105$196.24KSep 22, 2026Stock Option Exercise
Noah Berkowitz
Former Officer
Sep 9, 202637,200$328.91KSep 9, 2026Exercise of Options Under a Registered Plan
Noah Berkowitz
Former Officer
Sep 4, 20268,300$78.44KSep 4, 2026Exercise of Options Under a Registered Plan
Noah Berkowitz
Officer
Aug 4, 202630,000$264.00KAug 4, 2026Restricted Stock Vesting Under a Registered Plan
Noah Berkowitz
Former Affiliate
Jul 9, 202624,000$201.53KJul 9, 2026Restricted Stock Vesting Under a Registered Plan
Andrew Saik
Officer
Jun 23, 20265,846$47.59KJun 24, 2026Settlement of vested restricted stock units
Angela M. Cacace
Officer
Jun 17, 20262,642$19.60KJun 17, 2026Settlement of vested restricted stock units
Randy Teel
Officer, Director
May 20, 20262,197$19.99KMay 21, 2026Settlement of vested restricted stock units
Randy Teel
Officer, Director
May 8, 20269,834$99.42KMay 11, 2026Settlement of vested restricted stock units
Angela M. Cacace
Officer
May 8, 20269,834$99.42KMay 11, 2026Settlement of vested restricted stock units
Noah Berkowitz
Officer
May 8, 202611,312$114.36KMay 11, 2026Settlement of vested restricted stock units
Andrew Saik
Officer
May 8, 202611,343$114.68KMay 11, 2026Settlement of vested restricted stock units
Noah Berkowitz
Officer
Mar 17, 20266,022$72.32KMar 18, 2026Settlement of vested restricted stock units
John G. Houston
former President and CEO, Director
Feb 27, 202635,297$466.18KFeb 27, 2026Settlement of vested restricted stock units
Angela M. Cacace
Officer
Feb 23, 20263,609$43.90KFeb 23, 2026Settlement of vested restricted stock units

See a number that looks wrong?